ArticleCells2025
ucOCN Promotes Testosterone Synthesis via the PKA-MAPK/ERK-CREB Signaling Pathway in Porcine Leydig Cells.
Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Osteocalcin Beyond Bone: Molecular Mechanisms, Endocrine Networks, and Translational Perspectives Across Metabolism, Neurobiology, and Chronic Disease.International journal of molecular sciences · 2026Review
- Psoralen Promotes Direct Chemical Reprogramming of Mouse Embryonic Fibroblasts into Osteoblast-like Cells.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Bone health might be closely associated with male fertility, yet the molecular pathways remain poorly characterized. We demonstrate that undercarboxylated osteocalcin (ucOCN), a bone-derived hormone, initiates a signaling cascade that stimulates testosterone biosynthesis in porcine Leydig cells. Mechanistically, ucOCN binding to membrane receptor GPRC6A elevates intracellular cAMP levels and sequentially activates PKA, MEK, and ERK. ERK translocates to the nucleus and phosphorylates the transcription factor CREB. Activated CREB binds directly to promoter regions of the key steroidogenic genes and boosts testosterone production. The genetic or pharmacological inhibition of GPRC6A, PKA, MEK, or ERK signaling disrupts CREB activation and abolishes both steroidogenic gene expression and testosterone synthesis. Crucially, the phospho-switch S298 as a previously unrecognized phosphorylation site through which MEK regulates osteocalcin (OCN) signaling was identified. Collectively, our results indicate that ucOCN interacts with GPRC6A to promote testosterone synthesis in Leydig cells via the PKA-MAPK/ERK-CREB pathway. The above findings elucidate a fundamental endocrine axis between bone and the male reproductive system, offering novel mechanistic insights and potential therapeutic strategies for improving male fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.